US 12,403,174 B2
Immunomodulators
Tao Wang, Farmington, CT (US); Paul Michael Scola, Glastonbury, CT (US); and Zhongxing Zhang, Madison, CT (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Appl. No. 17/791,027
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
PCT Filed Nov. 19, 2020, PCT No. PCT/US2020/061273
§ 371(c)(1), (2) Date Jul. 6, 2022,
PCT Pub. No. WO2021/141684, PCT Pub. Date Jul. 15, 2021.
Claims priority of provisional application 62/957,383, filed on Jan. 6, 2020.
Prior Publication US 2023/0065827 A1, Mar. 2, 2023
Int. Cl. A61K 38/12 (2006.01); A61P 37/04 (2006.01)
CPC A61K 38/12 (2013.01) [A61P 37/04 (2018.01)] 13 Claims
 
1. A compound of formula (I)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
Rx and Ry are independently H,

OG Complex Work Unit Chemistry
provided that at least one of Rx and Ry is other than H;
R1 is H, halogen or C1-C6 alkyl;
R2 and R3 are independently H, halogen, C1-C6 alkyl, or aryl; said aryl group substituted with 0-3 R3a,
R3a is halogen or COOR4;
R4 is H or C1-C6 alkyl; and
R9 is H or C1-C3 alkyl.